Presence of hyperandrogenemia in cases evaluated due to menstrual irregularity, the effect of clinical and/or biochemical hyperandrogenemia on polycystic ovary syndrome
Journal of Pediatric Endocrinology and Metabolism · 2025
DOI: 10.1515/jpem-2025-0010 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Pediatric Endocrinology and Metabolism, 2025. Verfasst von Serkan Bilge Koca und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Division of Pediatric Endocrinology, Health Sciences University, Kayseri City Education and Research Hospital, Kayseri, Tur…. Hauptthemen laut MEDLINE: Polycystic Ovary Syndrome, Hyperandrogenism, Menstruation Disturbances, Biomarkers. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 27 Literaturangaben.
Abstract (Originalsprache)
Objectives
Polycystic ovary syndrome (PCOS) is known one of the most common causes of menstrual irregularities and hyperandrogenism in adolescents. We compared cases with increased risk for PCOS (presence of clinical hyperandrogenemia (CH) and/or biochemical hyperandrogenemia (BH) along with menstrual irregularity (MI)) and cases with only MI.
Methods
Patients were divided into four subgroups. Those with only MI (n=130), CH+MI (n=68), BH+MI (n=25), and CH+BH+MI (n=31). Age, weight, height, and body mass index were recorded. The CH was assessed by the presence of persistent acne, hirsutism, or androgenic alopecia. Modified Ferriman Gallwey (mFG) score was used to evaluate hirsutism. Cases with total testosterone levels above 55 ng/dL were considered to have BH.
Results
We observed that basal LH and LH/FSH ratio do not provide insight into CH. Unlike, DHEA-S (p=0.006), total testosterone (p=0.003), and free androgen index (FAI) (p=0.027) are relatively high in patients with CH. Polycystic ovarian morphology (PCOM) is lower in cases with only MI compared to cases with increased risk of PCOS (43.3 vs. 56.7 %, p=0.096). We predicted that 28.05 μg/L for Total testosterone, 75.9 for FAI, and 192.9 μg/dL for DHEA-S could be used as a cut-off value with a sensitivity and specificity over 60 %, to distinguish MI from increased risk for PCOS.
Conclusions
After excluding other secondary endocrinological causes of MI in the first years, routine use of total testosterone, DHEA-S, and FAI is sufficient to distinguish cases presenting menstrual disorders due to anovulation from increased risk of PCOS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, Division of Pediatric Endocrinology, Health Sciences University, Kayseri City Education and Research Hospital, Kayseri, Turkiye.
- Department of Pediatrics, Health Sciences University, Kayseri City Education and Research Hospital, Kayseri, Türkiye.
- Department of Pediatrics, Division of Pediatric Endocrinology, Ankara Bilkent City Hospital, Ankara, Türkiye.
ORCID-Profile: Serkan Bilge Koca, Esra Tengiç, Gönül Büyükyılmaz
Zitieren
APA
Koca, S. B., Tengiç, E., & Büyükyılmaz, G. (2025). Presence of hyperandrogenemia in cases evaluated due to menstrual irregularity, the effect of clinical and/or biochemical hyperandrogenemia on polycystic ovary syndrome. Journal of Pediatric Endocrinology and Metabolism. https://doi.org/10.1515/jpem-2025-0010
Vancouver
Koca SB, Tengiç E, Büyükyılmaz G. Presence of hyperandrogenemia in cases evaluated due to menstrual irregularity, the effect of clinical and/or biochemical hyperandrogenemia on polycystic ovary syndrome. Journal of Pediatric Endocrinology and Metabolism. 2025. doi:10.1515/jpem-2025-0010
BibTeX
@article{Koca2025,
author = {Koca, Serkan Bilge and Tengiç, Esra and Büyükyılmaz, Gönül},
title = {Presence of hyperandrogenemia in cases evaluated due to menstrual irregularity, the effect of clinical and/or biochemical hyperandrogenemia on polycystic ovary syndrome},
journal = {Journal of Pediatric Endocrinology and Metabolism},
year = {2025},
doi = {10.1515/jpem-2025-0010}
}
EUVIMED